- Home
- Publications
- Publication Search
- Publication Details
Title
γδ T cells for cancer immunotherapy
Authors
Keywords
-
Journal
OncoImmunology
Volume 3, Issue 1, Pages e27572
Publisher
Informa UK Limited
Online
2014-04-11
DOI
10.4161/onci.27572
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain
- (2013) Takamichi Izumi et al. CYTOTHERAPY
- Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
- (2013) Marina Chiara Garassino et al. LANCET ONCOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression Patterns of Killer Cell Immunoglobulin-Like Receptors (KIR) of NK-Cell and T-Cell Subsets in Old World Monkeys
- (2013) Meike Hermes et al. PLoS One
- Adoptive Cellular Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
- (2013) Xiaoyi Tang et al. PLoS One
- Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside
- (2012) Mounia S. Braza et al. BRITISH JOURNAL OF HAEMATOLOGY
- What lessons can be learned from γδ T cell-based cancer immunotherapy trials?
- (2012) Jean-Jacques Fournié et al. Cellular & Molecular Immunology
- Human γδ T-cell responses in infection and immunotherapy: Common mechanisms, common mediators?
- (2012) Chiara Riganti et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Ipilimumab in prostate cancer
- (2012) Nishith Singh et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Human T Lymphocytes Are Licensed for Professional Antigen Presentation by Interaction with Opsonized Target Cells
- (2012) N. Himoudi et al. JOURNAL OF IMMUNOLOGY
- Interaction Between Invariant NKT Cells and Myeloid-derived Suppressor Cells in Cancer Patients
- (2012) Francis Mussai et al. JOURNAL OF IMMUNOTHERAPY
- Tumor-promoting Versus Tumor-antagonizing Roles of γδ T Cells in Cancer Immunotherapy
- (2012) Volker Kunzmann et al. JOURNAL OF IMMUNOTHERAPY
- Potential of human γδ T cells for immunotherapy of osteosarcoma
- (2012) Zhaoxu Li MOLECULAR BIOLOGY REPORTS
- Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the c cytokines and TGF- 1
- (2011) Y. P. Park et al. BLOOD
- Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours
- (2011) A J Nicol et al. BRITISH JOURNAL OF CANCER
- Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma
- (2011) Hirohito Kobayashi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma
- (2011) Joshua M. Lang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote V 9V 2 T-Cell Chemotaxis and Cytotoxicity In Vivo
- (2011) I. Benzaid et al. CANCER RESEARCH
- Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies
- (2011) Jianhua Zhou et al. Cellular & Molecular Immunology
- γδ T-APCs: a novel tool for immunotherapy?
- (2011) Bernhard Moser et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Stimulated T Cells Increase the In Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer
- (2011) A.-H. Capietto et al. JOURNAL OF IMMUNOLOGY
- Adoptive Immunotherapy for Advanced Non-small CellLung Cancer Using Zoledronate-expanded γδTCells
- (2011) Miki Sakamoto et al. JOURNAL OF IMMUNOTHERAPY
- Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study
- (2011) David F. Heigener et al. LUNG CANCER
- Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
- (2011) John Koreth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors
- (2010) Jaafar Bennouna et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous γδ T cells☆☆☆
- (2010) Jun Nakajima et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody
- (2010) M. S. Braza et al. HAEMATOLOGICA
- Bromohydrin Pyrophosphate-stimulated Vγ9δ2 T Cells Expanded Ex Vivo From Patients With Poor-Prognosis Neuroblastoma Lyse Autologous Primary Tumor Cells
- (2010) Jamel Chargui et al. JOURNAL OF IMMUNOTHERAPY
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
- (2010) Gareth J Morgan et al. LANCET
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies
- (2009) J. Gertner-Dardenne et al. BLOOD
- The NKG2D ligand ULBP4 binds to TCR 9/ 2 and induces cytotoxicity to tumor cells through both TCR and NKG2D
- (2009) Y. Kong et al. BLOOD
- A regulatory cross-talk between Vγ9Vδ2 T lymphocytes and mesenchymal stem cells
- (2009) Ludovic Martinet et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma
- (2009) Yu Abe et al. EXPERIMENTAL HEMATOLOGY
- γδ T Cells and the Lymphoid Stress-Surveillance Response
- (2009) Adrian C. Hayday IMMUNITY
- Pitfalls on the roadmap to γδ T cell-based cancer immunotherapies
- (2009) Ludovic Martinet et al. IMMUNOLOGY LETTERS
- The bisphosphonate zoledronic acid has antimyeloma activityin vivoby inhibition of protein prenylation
- (2009) Andreas Guenther et al. INTERNATIONAL JOURNAL OF CANCER
- Human T Cells: A Lymphoid Lineage Cell Capable of Professional Phagocytosis
- (2009) Y. Wu et al. JOURNAL OF IMMUNOLOGY
- Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma
- (2008) Jaafar Bennouna et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CD16+ γδ T cells mediate antibody dependent cellular cytotoxicity: Potential mechanism in the pathogenesis of multiple sclerosis
- (2008) Zhihong Chen et al. CLINICAL IMMUNOLOGY
- Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy*
- (2008) M. Kondo et al. CYTOTHERAPY
- Inhibition of phosphoantigen-mediated γδ T-cell proliferation by CD4+ CD25+ FoxP3+regulatory T cells
- (2008) Volker Kunzmann et al. IMMUNOLOGY
- Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab
- (2008) Hirotake Tokuyama et al. INTERNATIONAL JOURNAL OF CANCER
- Docetaxel Plus Prednisolone for the Treatment of Metastatic Hormone-refractory Prostate Cancer: A Multicenter Phase II Trial in Japan
- (2008) S. Naito et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer
- (2008) Jean-Pascal Machiels et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnosis and treatment of prostate cancer: summary of NICE guidance
- (2008) John Graham et al. BMJ-British Medical Journal
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now